B7-H3.CD28Z.CART cell therapy (National Institutes Of Health)

N/A

Report date: 2026/02/06 20:01:23

Base Information

Drug NameB7-H3.CD28Z.CART cell therapy (National Institutes Of Health)
Drug Alias Nameb7-h3.cd28z.Cart)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionCD276 antigen modulators
TargetsCD276 antigen
Therapy Area/IndicationsMeningeal NeoplasmsBrain NeoplasmsCentral Nervous System Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Institutes Of Health
China Registration ClassN/A

Develop Information

Active CompaniesNational Institutes Of Health
Inactive CompaniesN/A
Active IndicationsMeningeal NeoplasmsBrain NeoplasmsCentral Nervous System Neoplasms +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A